A synthetic peptide analog of alpha-MSH used to treat hypoactive sexual desire disorder by activating melanocortin receptors to enhance sexual arousal.
The paper reviews new drugs for hot flashes and low sex drive in breast‑cancer patients on hormone therapy. It notes that current pills (SSRIs, gabapentin, etc.) often don’t work well, and highlights three newer options: fezolinetant for hot flashes, flibanserin for low libido, and bremelanotide (also called pt‑141) for sexual desire. However, none of these drugs have been tested in breast‑cancer patients, so doctors must weigh the risks before prescribing.
Barakeh. Donna D; Mdaihly. Hadil H; Karaoui. Lamis R LR
The review says that low sexual desire in pre‑menopausal women can be treated with a few drugs, mainly flibanserin (a daily pill) and bremelanotide (pt‑141, a shot taken before sex). Both are FDA‑approved but only give modest improvements and can cause side effects like nausea or blood‑pressure changes. Other drugs such as bupropion or buspirone are sometimes used off‑label, but the best results still come from combining medication with therapy and lifestyle changes.
Bhinder. Jashmira K JK; Kennedy. Samantha K F SKF; Faouk Al Aadah. Carmen C; Al-Khaifi. Muna M
The review looks at cancer survivorship guidelines for women’s sexual health and finds that all groups agree on using lubricants first, low‑dose estrogen if needed, and counseling or physical therapy for pain. Some guidelines list bremelanotide (pt‑141) as a possible drug for low libido, but they note there isn’t much data yet.
The analysis shows that bremelanotide (pt‑141) gives only small improvements in women's low sexual desire, but it causes many more side‑effects that make people drop out of studies, and most participants actually prefer staying on placebo. The original trial left out most of its planned results, so the drug’s real benefit is unclear and probably not worth the risk.
Mintzes. Barbara B; Tiefer. Leonore L; Cosgrove. Lisa L
The paper says the two FDA‑approved drugs for low sexual desire in women – flibanserin and bremelanotide – barely work, with flibanserin giving only about one extra enjoyable sex event every two months and bremelanotide showing no real benefit.
The paper explains that many men with erectile problems don’t get enough help from the usual pills (PDE5 inhibitors) and that doctors are looking at drugs that work in the brain to improve erections, like apomorphine, but it doesn’t give specific tips for using the peptide pt‑141.
Al Shaer. Danah D; Al Musaimi. Othman O; Albericio. Fernando F; de la Torre. Beatriz G BG
The 2019 FDA report shows that more peptide‑based drugs (called TIDES) were approved than in previous years, highlighting a growing trend for these molecules in medicine, but it doesn’t give any specific tips on how to use pt‑141 or other peptides.
Weinberger. James M JM; Houman. Justin J; Caron. Ashley T AT; Patel. Devin N DN; Baskin. Avi S AS; A...
A big review found that when women with sexual problems take a fake pill (placebo), their sexual function scores go up a lot, and real drugs only do a little better, meaning most of the benefit comes from the placebo effect.
The article is a clinical review of seven newly FDA‑approved drugs, describing their medical uses, safety warnings, side effects, and nursing care notes. It doesn’t give any specific guidance on using the peptide PT‑141 for self‑experimentation or performance enhancement.
Stanley. Elizabeth E EE; Pfoh. Elizabeth E; Lipold. Laura L; Martinez. Kathryn K
The study looks at how primary care doctors treat female sexual dysfunction (FSD) versus male erectile dysfunction (ED). It finds that women diagnosed by primary care doctors are less likely to get treatment compared to men, highlighting a care gap for female patients.
The paper reviews 12 new psychiatric drugs approved by the FDA between 2018 and 2022, focusing on their clinical need, safety, and how they might shape future psychopharmacology. It does not mention the peptide PT‑141 at all, so it offers no direct guidance for using that peptide.
The paper talks about low sexual desire in women, how doctors can talk about it, and what current treatments like bupropion might help. It does not mention the peptide pt-141 at all, so it offers no direct guidance for using that peptide.
Saffati. Gal G; Naeem. Taher T; Kaaki. Basil B; Khera. Mohit M
A single case report describes a 28‑year‑old man with lifelong anorgasmia who finally had an orgasm after taking the female‑focused drug flibanserin for about a month. He also reported nighttime urination and trouble sleeping, and his overall sexual satisfaction barely changed.